Rebecca A. Smirk
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Peroxisome Proliferator-Activated Receptors, Biochemical and Molecular Research, Blood Coagulation and Thrombosis Mechanisms
Most-Cited Works
- → Discovery of an Oxybenzylglycine Based Peroxisome Proliferator Activated Receptor α Selective Agonist 2-((3-((2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic Acid (BMS-687453)(2010)40 cited
- → Pyridine amides as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1(2008)23 cited
- → Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold(2013)15 cited
- → Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists(2015)11 cited
- → Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132)(2022)9 cited
- → Discovery of liver-selective glucokinase activators comprising N-(4-alkylthiazol-2-yl)benzamides and N-(3-alkyl-1,2,4-thiadiazol-5-yl)benzamides for the treatment of metabolic disorders(2025)